DXCM Dexcom Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DXCM

Price (delayed)

$105.915

Market cap

$40.91B

P/E Ratio

179.52

Dividend/share

N/A

EPS

$0.59

Enterprise value

$42.28B

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in ...

Highlights
Dexcom's revenue has increased by 20% YoY and by 4.5% from the previous quarter
DXCM's gross profit is up by 13% year-on-year and by 2.7% since the previous quarter
The EPS has shrunk by 61% YoY but it rose by 5% QoQ
Dexcom's net income has plunged by 60% YoY but it has increased by 6% from the previous quarter
The quick ratio has declined by 26% year-on-year and by 21% since the previous quarter
The company's equity fell by 19% QoQ and by 15% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.dexcom.com/
Peers: EW BDX WST TNDM

Key stats

What are the main financial stats of DXCM
Market
Shares outstanding
386.26M
Market cap
$40.91B
Enterprise value
$42.28B
Valuations
Price to earnings (P/E)
179.52
Price to book (P/B)
22.79
Price to sales (P/S)
14.78
EV/EBIT
150.75
EV/EBITDA
97.83
EV/Sales
15.14
Earnings
Revenue
$2.79B
EBIT
$280.5M
EBITDA
$432.2M
Free cash flow
$261.3M
Per share
EPS
$0.59
Free cash flow per share
$0.67
Book value per share
$4.65
Revenue per share
$7.16
TBVPS
$12.44
Balance sheet
Total assets
$4.9B
Total liabilities
$3.07B
Debt
$2.07B
Equity
$1.82B
Working capital
$2.5B
Liquidity
Debt to equity
1.14
Current ratio
3.77
Quick ratio
3.26
Net debt/EBITDA
3.18
Margins
EBITDA margin
15.5%
Gross margin
65%
Net margin
8.2%
Operating margin
9.5%
Efficiency
Return on assets
4.6%
Return on equity
11.1%
Return on invested capital
5.1%
Return on capital employed
7%
Return on sales
10%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DXCM stock price

How has the Dexcom stock price performed over time
Intraday
-0.75%
1 week
-0.46%
1 month
-6.47%
1 year
2.48%
YTD
-6.47%
QTD
-6.47%

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$2.79B
Gross profit
$1.81B
Operating income
$266.4M
Net income
$230M
Gross margin
65%
Net margin
8.2%
The net margin has plunged by 67% YoY
Dexcom's net income has plunged by 60% YoY but it has increased by 6% from the previous quarter
The operating margin has declined by 40% year-on-year but it has increased by 7% since the previous quarter
DXCM's operating income is down by 28% year-on-year but it is up by 12% since the previous quarter

Growth

What is Dexcom's growth rate over time

Valuation

What is Dexcom stock price valuation
P/E
179.52
P/B
22.79
P/S
14.78
EV/EBIT
150.75
EV/EBITDA
97.83
EV/Sales
15.14
The EPS has shrunk by 61% YoY but it rose by 5% QoQ
The stock's price to earnings (P/E) is 10% less than its last 4 quarters average of 202.1
The company's equity fell by 19% QoQ and by 15% YoY
DXCM's P/B is 17% above its last 4 quarters average of 19.6 and 12% above its 5-year quarterly average of 20.5
Dexcom's revenue has increased by 20% YoY and by 4.5% from the previous quarter
The stock's price to sales (P/S) is 5% less than its last 4 quarters average of 15.7

Efficiency

How efficient is Dexcom business performance
Dexcom's ROA has plunged by 64% YoY but it has increased by 7% from the previous quarter
The ROE has dropped by 62% year-on-year but it is up by 11% since the previous quarter
The ROS fell by 38% YoY but it rose by 6% QoQ
DXCM's return on invested capital is down by 37% year-on-year but it is up by 6% since the previous quarter

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 59% higher than its total liabilities
The quick ratio has declined by 26% year-on-year and by 21% since the previous quarter
Dexcom's current ratio has decreased by 24% YoY and by 20% QoQ
The debt is 14% more than the equity
DXCM's debt to equity is up by 34% YoY and by 24% QoQ
The company's equity fell by 19% QoQ and by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.